Thierry Facon, MD, of Centre Hospitalier Universitaire (CHU) Lille discusses the latest results from TOURMALINE-MM2 study presented at ASH 2020.

TOURMALINE-MM2 is a phase 3 clinical trial that compared oral ixazomib, lenalidomide, and dexamethasone to placebo, lenalidomide, and dexamethasone in patients with multiple myeloma

Multiple myeloma is a rare blood cancer characterized by excessive growth of malignant plasma cells in the bone marrow. Individuals with multiple myeloma develop significant osteolytic bone lesions and have immunodeficiency that compromise their longevity and quality of life.

Most patients with multiple myeloma are elderly and may not be eligible for stem cell transplant. The TOURMALINE-MM2 was designed to see of having an all oral treatment with ixazomib would be a safe and effective alternative.

As Dr. Facon explains in this video, the addition of ixazomib led to a clinically meaningful, albeit non-statistically significant improvement in progressive free survival (PFS). In newly diagnosed patients with multiple myeloma taking ixazomib in combination with lenalidomide and dexamethasone, PFS was 35.23 months (N=351) compared to 21.8 months in the control group (N=354). The all oral therapy was generally well tolerated and Dr. Facon believes it is a feasible treatment option for certain patients in which travelling to an infusion center is problematic.

свернуть